SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules.
Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.
Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their R&D goals
Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.
Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.
Learn from our client PharmAust, how drug repurposing is an effective alternative approach to traditional drug discovery, the changing landscape of drug repurposing, steps in the drug repurposing journey when moving up to GMP scale and more.
Learn from our client ApconiX, the key trends in the toxicology space, how AI and in vitro studies co-exist and support an overarching tox strategy and more.
Learn from our client, Merck & Co., the relevance of PK and ADA data in a clinical setting, impact of neutralizing antibodies on PK and more.
Listen to what our client, C4 Therapeutics has to say, about the exciting opportunity that Targeted Protein Degradation represents to Biopharma companies around the world.
Our client, Albireo, recently cleared phase-3 clinical trials for its drug Odevixibat. Learn from Albireo’s experience, how to advance molecules from discovery to the clinic in the shortest possible time.
Syngene-Baxter R& D Centre is going strong even after 10 years. Undertand from our experts, the key elements of a great research partnership in ICH Stability Studies.
© 2024. Syngene International Limited